Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BXCL701 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BXCL701 plus Pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BXCL701 | DRUG | BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days |
| Pembrolizumab | DRUG | Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days. |
Inclusion Criteria: * Histologically-confirmed pancreatic ductal adenocarcinoma with metastatic disease (mixed histology is acceptable as long adenocarcinoma is the dominant histological subtype) * Patient must consent to two mandatory biopsies and have tumor amenable to serial core biopsies * Meas...
BXCL701 is an investigational small molecule being studied for the treatment of metastatic pancreatic ductal adenocarcinoma and prostate cancer. It is currently in Phase 2 clinical development for these oncology indications.
BXCL701 is a small molecule being developed for oncology indications. Its specific molecular target has not been disclosed in available information.
BXCL701 is being developed by BioXcel Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol BTAI.
BXCL701 is in Phase 2 clinical development. It has received Fast Track and Orphan Drug designations from the FDA for its oncology indications.
BXCL701 is being studied in two clinical trials. NCT03910660 is a completed Phase 1 trial combining BXCL701 with pembrolizumab in prostate cancer. NCT05558982 is an active Phase 2 trial of BXCL701 with pembrolizumab in metastatic pancreatic ductal adenocarcinoma.
BXCL701 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for metastatic pancreatic ductal adenocarcinoma and prostate cancer.